Australian and US researchers have genetically engineered a novel antithrombotic drug, which binds only to activated platelets at the site of a thrombus. By only binding to activated platelets, not sealing platelets, there is no risk of bleeding complications with the recombinant fusion protein known as Targ-TAP. Targ-TAP consists of a single-chain antibody that targets ...
Novel antiplatelet agent engineered
By Mardi Chapman
16 Jul 2019